SLC6A3

Across TCGA pan-cancer cohorts, SLC6A3 RNA differs between tumor and matched normal tissue in 11 of 18 cancer types tested, making tumor–normal expression one of SLC6A3’s most consistent transcriptional readouts.

The strongest signal is observed in kidney renal clear cell carcinoma (KIRC), where SLC6A3 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SLC6A3 is over-expressed in tumor, although a few such as THCA and KICH show the opposite, repressed pattern.

KIRC, THCA, and KICH are the cancer types where SLC6A3 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SLC6A3 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
KIRC	Female	All	+4.901	<.001	12	view →
THCA	Female	II,III,IV	−1.224	<.001	11	view →
KICH	Male	All	−0.632	<.001	8	view →
HNSC	All	All	+0.117	.011	7	view →
COAD	All	II,III,IV	+0.061	<.001	6	view →
LUAD	Female	All	+1.215	<.001	5	view →
UCEC	All	All	−0.471	<.001	4	view →
LIHC	All	All	+0.076	.013	4	view →
LUSC	Female	II,III,IV	−0.411	.015	2	view →
PRAD	All	All	+0.307	.001	2	view →
CHOL	All	All	+0.242	.015	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 11 strongest of 11 lineages.

SLC6A3–KIRC

Open the KIRC breakdown →